Enanta Pharmaceuticals Inc ENTA
$13.47 $0.34 (2.59%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
ENTA Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Enanta Pharmaceuticals Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Enanta Pharmaceuticals Inc. Stock Analysis ENTA
United States Health Care Small Cap Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 120 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Enanta Pharmaceuticals Inc (ENTA) Chart
Financial Metrics & Statements of Enanta Pharmaceuticals Inc (ENTA)
FAQ's for Enanta Pharmaceuticals Inc (ENTA)
- As of August 2026, Enanta Pharmaceuticals Inc ENTA is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Enanta Pharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Enanta Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Enanta Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Enanta Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Enanta Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Enanta Pharmaceuticals Inc (ENTA)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
